Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of PSN821 in type 2 diabetes after Ensure Plus challenge
2010-023182-22Phase 2Completed
- Sponsor
- Prosidion Ltd.
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of PSN821 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Prosidion Ltd. Primary endpoint: Primary pharmacodynamic endpoint. Started Nov 2010; status: completed.
02
Drugs
PSN821
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2010-023182-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-023182-22.